Literature DB >> 10713915

Postoperative sympathetic ophthalmia.

A T Gasch1, C S Foster, C L Grosskreutz, L R Pasquale.   

Abstract

Although uncommon, SO is a fearful postoperative complication because of its potential to blind both eyes. It can result not only from penetrating ocular surgery but also from nonpenetrating ocular procedures. Thus, it is important to consider in any patient who has undergone ocular surgery and develops bilateral uveitis, particularly because prompt, sufficient treatment is required to maximize visual outcome. It is also important to note that the disease may present with a spectrum of clinical findings, none of which is pathognomonic. Thus, suspicion is important for making the diagnosis. Treatment should address the T-cell-mediated nature of the disease. With appropriate treatment, visual acuity of no less than 20/60 is likely. However, before the start of treatment, which consists of immunosuppressants, infection must be ruled out and potential side effects of treatments must be considered. Furthermore, any patient with a history of SO needs ample immunosuppressant coverage for ocular procedures. Better understanding of the pathogenesis of the disease may lead to safer treatments that result in improved visual outcome and a cure. Meanwhile, because of its relapsing nature, SO requires continual, close surveillance, even after many years of quiescence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713915     DOI: 10.1097/00004397-200040010-00008

Source DB:  PubMed          Journal:  Int Ophthalmol Clin        ISSN: 0020-8167


  10 in total

1.  Postsurgical sympathetic ophthalmia: retrospective analysis of a rare entity.

Authors:  Parthopratim Dutta Majumder; Eliza Anthony; Amala Elizabeth George; Sudha K Ganesh; Jyotirmay Biswas
Journal:  Int Ophthalmol       Date:  2017-11-21       Impact factor: 2.031

2.  Sympathetic ophthalmia in Singapore: new trends in an old disease.

Authors:  Daniel Hsien-Wen Su; Soon-Phaik Chee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-19       Impact factor: 3.117

3.  Sympathetic ophthalmia: what have we learned?

Authors:  H Nida Sen; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2009-11       Impact factor: 5.258

Review 4.  Sympathetic ophthalmia.

Authors:  Claudia Patricia Castiblanco; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-16       Impact factor: 3.117

5.  Sympathetic ophthalmia after surgical resection of iridociliary melanoma. A case report.

Authors:  Jose Garcia-Arumi; Marc Montolio Gil; Merce Morral Palau; Antonio Segura Garcia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

6.  Evisceration in the modern age.

Authors:  Laura T Phan; Thomas N Hwang; Timothy J McCulley
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

7.  Cyclophotocoagulation-induced sympathetic ophthalmia in a Coats' disease patient supported by histopathology and immunohistochemistry.

Authors:  Pritam Bawankar; Dipankar Das; Shahinur Tayab; Ganesh Chandra Kuri; Jnanankar Medhi; Manabjyoti Barman; Ronel Soibam; Harsha Bhattacharjee; Panna Deka; Diva Kant Misra; Shriya Dhar
Journal:  Indian J Ophthalmol       Date:  2017-08       Impact factor: 1.848

8.  Effective treatment of refractory sympathetic ophthalmia with glaucoma using adalimumab.

Authors:  Tomona Hiyama; Yosuke Harada; Yoshiaki Kiuchi
Journal:  Am J Ophthalmol Case Rep       Date:  2019-01-25

9.  Commentary: Optical coherence tomography in sympathetic ophthalmia.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

10.  Enucleation and evisceration at a tertiary care hospital in a developing country.

Authors:  Osama H Ababneh; Eman A AboTaleb; Mohammad A Abu Ameerh; Yacoub A Yousef
Journal:  BMC Ophthalmol       Date:  2015-09-11       Impact factor: 2.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.